A carregar...

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

INTRODUCTION: Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Ther
Main Authors: Sunkureddi, Prashanth, Latremouille-Viau, Dominick, Meiselbach, Mark K., Xie, Jipan, Hur, Peter, Joshi, Reeti
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6393268/
https://ncbi.nlm.nih.gov/pubmed/30612321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-018-0137-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!